Clinical trialNCT00398879CompletedPhase 2Interventional

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients

SponsorAEterna ZentarisEnrollment381Colon Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal cancer which would be randomized to either capecitabine plus perifosine or capecitabine alone. The effects of perifosine may be manifested by increased time to progression, tumor regression reflected in partial or complete responses, or a combination of these outcomes. The primary goal of this trial is to obtain a preliminary and objective assessment of the effects of perifosine on time to progression.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Craig Henderson, MD
Online Collaborative Oncology Group
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Aoi Pharmaceuticals Investigative Site
Tucson, Arizona, United States
Aoi Pharmaceuticals Investigative Site
Beverly Hills, California, United States
Aoi Pharmaceuticals Investigative Site
Deer Park, California, United States
Aoi Pharmaceuticals Investigative Site
Monterey, California, United States
Aoi Pharmaceuticals Investigative Site
Newport Beach, California, United States
Aoi Pharmaceuticals Investigative Site
Pomona, California, United States
Aoi Pharmaceuticals Investigative Site
Santa Rosa, California, United States
Aoi Pharmaceuticals Investigative Site
Soquel, California, United States
Aoi Pharmaceuticals Investigative Site
Stockton, California, United States
Aoi Pharmaceuticals Investigative Site
Colorado Springs, Colorado, United States
Aoi Pharmaceuticals Investigative Site
Greeley, Colorado, United States
Aoi Pharmaceuticals Investigative Site
Middletown, Connecticut, United States
Aoi Pharmaceuticals Investigative Site
Norwich, Connecticut, United States
Aoi Pharmaceuticals Investigative Site
Aventura, Florida, United States
Aoi Pharmaceuticals Investigative Site
Coral Springs, Florida, United States
Aoi Pharmaceuticals Investigative Site
Lake City, Florida, United States
Aoi Pharmaceuticals Investigative Site
Miami, Florida, United States
Aoi Pharmaceuticals Investigative Site
Ormond Beach, Florida, United States
Aoi Pharmaceuticals Investigative Site
Sebastian, Florida, United States
Aoi Pharmaceuticals Investigative Site
Vero Beach, Florida, United States
Aoi Pharmaceuticals Investigative Site
Augusta, Georgia, United States
Aoi Pharmaceuticals Investigative Site
Lawrenceville, Georgia, United States
Aoi Pharmaceuticals Investigative Site
Marietta, Georgia, United States
Aoi Pharmaceuticals Investigative Site
Galesburg, Illinois, United States
Aoi Pharmaceuticals Investigative Site
Park Ridge, Illinois, United States
Aoi Pharmaceuticals Investigative Site
Louisville, Kentucky, United States
Aoi Pharmaceuticals Investigative Site
Lafayette, Louisiana, United States
Aoi Pharmaceuticals Investigative Site
Grand Rapids, Michigan, United States
Aoi Pharmaceuticals Investigative Site
Kalamazoo, Michigan, United States
Aoi Pharmaceuticals Investigative Site
Branson, Missouri, United States
Aoi Pharmaceuticals Investigative Site
Billings, Montana, United States
Aoi Pharmaceuticals Investigative Site
Great Falls, Montana, United States
Aoi Pharmaceuticals Investigative Site
Albany, New York, United States
Aoi Pharmaceuticals Investigative Site
Armonk, New York, United States
Aoi Pharmaceuticals Investigative Site
Great Neck, New York, United States
Aoi Pharmaceuticals Investigative Site
Wilmington, North Carolina, United States
Aoi Pharmaceuticals Investigative Site
Dayton, Ohio, United States
Aoi Pharmaceuticals Investigative Site
Pottsville, Pennsylvania, United States
Aoi Pharmaceuticals Investigative Site
Sayre, Pennsylvania, United States
Aoi Pharmaceuticals Investigative Site
Greenville, South Carolina, United States

9 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Capecitabine →Perifosine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2005
Primary completion: 31 Dec 2010
Completion: 31 Oct 2011
Last update posted: 14 Mar 2018
Registered enrollment: 381
Registry id: NCT00398879

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.